MedTrace Logo

EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)

NCT04515043 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-06-01

No results posted yet for this study

Summary

This study will be an exploratory study of long term immunogenicity of INVAC-1 in patients who participated in the INVAC1-CT-101 phase I study (between 2014 and 2018).

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.

blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine

Sponsors & Collaborators

  • Invectys

    lead INDUSTRY

Principal Investigators

  • Luis Teixeira · AP-HP Paris Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-16
Primary Completion
2020-12-19
Completion
2020-12-19

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04515043 on ClinicalTrials.gov